Partnering Oncotide is seeking partners for preclinical and clinical development of our leads for hematological cancers and selected solid tumors. For more information, please contact Dr. Anil Goyal, V.P. of Business Development Print this page ...

Management Team Mike Vitek, Ph.D. - Chief Executive Officer Dr. Vitek is the Founder and CEO of Cognosci, Inc. since 2000 and is an Associate Professor at Duke University Medical Center, Department of Neurobiology and the Department of Medicine, Division of Neurology. He previously worked at Glaxo-W...

Publications SET Oncoprotein Overexpression in B-cell Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma: A Predictor of Aggressive Disease and a New Treatment Target. Christensen D.J., Chen Y., Oddo J., Matta K.M., Neil J., Davis E.D., Volkheimer A.D., Lanasa M.C., Friedman D.R., Goodman B.K., G...

Oncotide Pharmaceuticals Inc. was founded in February 2011 to develop compounds for oncology that act by restoration of the activity of the protein phosphatase 2A (PP2A) tumor suppressor. It has been demonstrated that inhibition of PP2A is required to convert a normal cell into a transformed tumor-f...

Contact Information Oncotide Pharmaceuticals 79 T. W. Alexander Drive Building 4401, Suite 200A Research Triangle Park NC 27709 Phone: 1-919-801-2911 email: Click here to contact us Directions From the East/RDU Airport: Take I-40 West toward Chapel Hill Exit on 279A to Rt. 147 South (Durham Freeway ...